verbatim applicant s based previous using calpain inhibitor leupeptin acetylleucylleucylarginal inhibit muscle wasting animal models muscular dystrophy denervation atrophy investigators devised unique method active portion leupeptin molecule directly targeted affected tissue chemically linking appropriate carrier molecules normally concentrated tissue active transport 20100 fold plasma levels carnitine muscle taurine nerve cells act carriers shown preliminary chemical entity carnitylleucylargininal least 13 fold effective inhibiting calpain intracellularly skeletal muscle leupeptin alone purpose expand initial observations towards development compounds therapeutic agents treatment variety neuromuscular neurodegenerative disorders proposed commercial application available